Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KCNQ3 | O43525 | 3/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.34 |
| ▸ | KCNE1 | P15382 | 3/20 | 0.34 |
| ▸ | KCNQ1 | P51787 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.32 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.32 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.32 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29577063 | 1.00 | NNMT (0.42) | NNMTNAPRTSIRT6TSHRCASP1 | |
| SCHEMBL28662886 | 0.86 | NNMT (0.42) | NNMTNAPRTSIRT6TSHRCASP1 | |
| SCHEMBL29446081 | 0.84 | SMN1; SMN2 (0.47) | NNMTNAPRTSIRT6TSHRCASP1 | |
| SCHEMBL625580 | 0.84 | SMN1; SMN2 (0.47) | NNMTNAPRTSIRT6TSHRCASP1 | |
| SCHEMBL29799541 | 0.83 | NNMT (0.61) | NNMTSIRT6KMT2A | |
| SCHEMBL13304188 | 0.83 | NNMT (0.43) | NNMTNAPRTSIRT6SMN1; SMN2KDM4E | |
| SCHEMBL29562604 | 0.83 | NNMT (0.43) | NNMTNAPRTSIRT6SMN1; SMN2KDM4E | |
| SCHEMBL27417396 | 0.83 | NNMT (0.40) | NNMTNAPRTSIRT6TSHRCASP1 | |
| SCHEMBL384113 | 0.83 | NNMT (0.61) | NNMTSIRT6KMT2A | |
| SCHEMBL30851435 | 0.82 | KDM4E (0.53) | NNMTSIRT6KDM4EMAPTKCNQ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2025242908-A2 | NOVEL COMPOUNDS | GENOME THERAPEUTICS LTD (GB) | 2025-11-27 | — | — | WO | disclosed |
| US-20250313561-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | RYVU THERAPEUTICS S A (PL) | 2025-10-09 | — | — | US | disclosed |
| US-12365667-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-07-22 | — | — | US | disclosed |
| US-12344606-B2 | Next-generation modulators of stimulator of interferon genes (STING) | Ryvu Therapeutics S.A. (PL) | 2025-07-01 | — | — | US | disclosed |
| WO-2025133338-A1 | QUINOLONE DERIVATVES AGAINST CANCER | GENOME THERAPEUTICS LTD (GB) | 2025-06-26 | — | — | WO | disclosed |
| EP-4551560-A1 | HALOALKYLPYRIDYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR | Huyabio International, LLC (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-113620949-B | Synthesis method of antitumor compound and intermediate thereof | 药捷安康(南京)科技股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-12240840-B2 | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-03-04 | — | — | US | disclosed |
| WO-2024220937-A2 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-9951064-B2 | Azaindazole compounds as inhibitors of T790M containing EGFR mutants | GENENTECH, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951064-B2 | Azaindazole compounds as inhibitors of T790M containing EGFR mutants | GENENTECH, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| CN-107406452-A | Pyrazolo [3,4 d] pyrimidine derivatives and its purposes for treating leishmaniasis | 葛兰素史密斯克莱知识产权发展有限公司 | 2017-11-28 | — | — | CN | disclosed |
| WO-2017191304-A1 | TETRAHYDROPYRIMIDODIAZEPINE AND TETRAHYDROPYRIDODIAZEPINE COMPOUNDS FOR TREATING PAIN AND PAIN RELATED CONDITIONS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-11-09 | — | — | WO | disclosed |
| US-20160257682-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160257682-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160257682-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2016-09-08 | — | — | US | disclosed |
| EP-3052494-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | Genentech, Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| WO-2014210354-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014210354-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | NNMT 871/4885NAPRT 1987/4885SIRT6 1315/4885 |
| US-12344606-B2 | Next-generation modulators of stimulator of interferon genes (STING) | STING1, IRF3, CGAS | NNMT 320/4885NAPRT 1351/4885SIRT6 3614/4885 |
| US-20250313561-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | NNMT 320/4885NAPRT 1351/4885SIRT6 3614/4885 |
| US-12365667-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | TYK2, JAK3, JAK2 | NNMT 2813/4885NAPRT 3008/4885SIRT6 1115/4885 |
| US-20160257682-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | EGFR, ERBB2, ERBB3 | NNMT 1012/4885NAPRT 1847/4885SIRT6 2952/4885 |
| US-12240840-B2 | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha | TYK2, IFNG, JAK3 | NNMT 2555/4885NAPRT 3347/4885SIRT6 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.